Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +18.84%
#2 Storj Storj +13.26%
#3 Fake World Assets Fake World Assets +7.59%
#4 OriginTrail OriginTrail +6.03%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +5.44%
#6 Geodnet Geodnet +5.34%
#7 Collector Crypt Collector Crypt +5.18%
#8 ApeX ApeX +4.55%
#9 OSK OSK +4.40%
#10 Ardor Ardor +4.39%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
設定
言語
日本
通貨
USD
テーマ
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
株式のランク #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
株価
$1.54
最終同期: 2024-04-08
時価総額
$119.21M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 NGM Biopharmaceuticals, Inc. (NGM)

カテゴリー

Healthcare
NGM Biopharmaceuticals, Inc.（NGM）の配当履歴
NGM Biopharmaceuticals, Inc.（証券コード：NGM）は合計で0回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
2026から2026までのNGM Biopharmaceuticals, Inc.（NGM）の配当履歴
年間配当支払い
年 配当（株式分割調整済み） 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
年 配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH